Technology

About CMN-001

How does our DC based technology activate your immune response?

CoImmune’s proprietary technology creates individualized immunotherapies that harness and reprogram dendritic cells to target antigens specific to each person’s disease. Each patients’ tumor is unique to each individual. Mutations or neoantigens in the tumor or over-expression of normal proteins can lead to malignant growth. Finding the right antigen is a challenge and has confounded many prior immuno-oncology strategies.

The scientists at CoImmune have overcome this challenge by taking advantage of the special place dendritic cells hold as master regulators of the immune system. We have engineered these cells to capture the spectrum of neoantigens and variant antigens that are specific to each patient’s individual disease. We designed these cells to overcome immunosuppression by enabling specifically targeted, durable memory T-cells.

manufacture process

Our process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a leukapheresis procedure. Our proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy.

CoImmune scientists have recognized that single therapeutic approaches have had only limited clinical success. Therefore, we have innovated a precise immunotherapeutic approach unlike any other with the potential to be revolutionary. This platform technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases. Our GMP manufacturing process is specifically designed to overcome many of the manufacturing and commercialization challenges that have impeded other cellular immunotherapies. Given the uniqueness of the technology and a strong safety profile we are well positioned to combine with other immuno-oncology agents.

Immunotherapeutics

Combination Therapy for Immuno-oncology

CoImmune is a cell therapy company designed to leverage your own immune system to fight disease. Our flagship program relies on the manufacturing of patient specific dendritic cells to treat their disease. Dendritic cells are like tiny sentinels – patrolling the body seeking out tumors and infected cells warning the immune system of oncoming disease. Given our strong safety profile of treating cancer and HIV patients with our DC based therapy, CoImmune is in a unique position to combine with other immuno-oncology agents to act in synergy to fight cancer and disease.

Immunomonitoring

From simple to complex, let CoImmune researchers help you connect the dots through the science of multi-color flow cytometry. Detection of cell surface molecules combined with intra cellular staining for function as defined by the expression of cytokines can reveal the immunological status pre and post treatment.

Read More

Our Process

Manufacturing of the coIMMUNE DC Final Product

CoImmune utilizes a proprietary, centralized manufacturing process that has substantial efficiency and cost advantages over first generation personalized immunotherapies.

Immunomonitoring

Flow Cytometry

CoImmune researchers can help you connect the dots through the science of multi-color flow cytometry. Detection of cell surface molecules combined with intra cellular staining for function as defined by the expression of cytokines can reveal the immunological status pre and post treatment. Our system is capable of detecting up to 18 different colors